AtriCure Reports Third Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
AtriCure Inc. (ATRC) PT Raised to $92 at Needham & Company
November 4, 2021 6:44 AM EDTNeedham & Company analyst Mike Matson raised the price target on AtriCure Inc. (NASDAQ: ATRC) to $92.00 (from $90.00) while maintaining a Buy rating.
The analyst commented, "ATRC's 3Q21 revenue, EBITDA, and EPS all beat consensus. While it has only been 6 months since EPi-Sense's FDA... More
AtriCure (ATRC) Tops Q3 EPS by 10c
November 3, 2021 4:39 PM EDTAtriCure (NASDAQ: ATRC) reported Q3 EPS of ($0.23), $0.10 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $70.5 million versus the consensus estimate of $68.68 million.
GUIDANCE:
AtriCure sees FY2021 EPS of ($1.20), versus the consensus of ($1.35). AtriCure... More
